Serum Adipocyte Fatty Acid Binding Protein Levels in Patients with Type 2 Diabetes Mellitus and Obesity: the Influence of Fenofibrate Treatment

M. M. HALUZÍK1,3, K. ANDERLOVÁ1, R. DOLEŽALOVÁ1, A. ADAMÍKOVÁ4, D. HALUZÍKOVÁ1,2, J. HOUSOVÁ1, Š. SVAČINA1, M. HALUZÍK1

1Third Department of Medicine, 2Department of Sports Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, 3Department of Chemistry, University of Ostrava, Ostrava and 4Diabetes Center, Bata Regional Hospital, Zlín, Czech Republic

Received August 8, 2007
Accepted November 28, 2007
On-line January 17, 2008

Summary
Recent studies have demonstrated that adipocyte fatty acid binding proteins (FABP) may play a role in the etiopathogenesis of insulin resistance. The aim of our study was to assess serum FABP levels in obese patients with type 2 diabetes mellitus (T2DM) before and after 3 months of treatment with PPAR-α agonist fenofibrate (F) and to explore the relationship of FABP to biochemical parameters and measures of insulin sensitivity assessed by hyperinsulinemic-isoglycemic clamp. We measured biochemical parameters by standard laboratory methods, insulin sensitivity by hyperinsulinemic-isoglycemic clamp and serum concentrations of FABP by commercial ELISA kit in 11 obese females with T2DM before and after three months of treatment with PPAR-α agonist fenofibrate and in 10 lean healthy control women (C). Serum FABP levels were 2.5-fold higher in T2DM group relative to C and were not affected by fenofibrate treatment (C: 20.6 ± 2.1 μg/l, T2DM before F: 55.6 ± 5.7 μg/l, T2DM after F: 54.2 ± 5.4 μg/l, p<0.0001 for C vs. T2DM before F).

Hyperinsulinemia during the clamp significantly suppressed FABP levels in both C and T2DM group. FABP levels positively correlated with BMI, triglyceride levels, blood glucose, glycated hemoglobin, atherogenic index and insulin levels. An inverse relationship was found between FABP and HDL levels, metabolic clearance rate of glucose, M/I and MCRglc/I sensitivity indexes. We conclude that FABP levels are closely related to BMI, parameters of insulin sensitivity, HDL levels and measures of diabetes compensation. This combination makes FABP a valuable marker of metabolic disturbances in patients with type 2 diabetes mellitus.

Key words
FABP • Insulin sensitivity • Diabetes • Obesity • Glucose clamp

Introduction
The close interconnection between obesity/insulin resistance, type 2 diabetes, dyslipidemia and several other pathologies within the so-called insulin resistance syndrome has been documented in numerous clinical studies (Reaven 1988, 1992). The combination of these pathologies represents a major risk factor for the development of accelerated atherosclerosis and its complications (Haffner 2003, Haffner et al. 1998). Insulin resistance is now considered a primary perturbation that in turn leads to other abnormalities (Shulman 2000). One of the possible etiopathogenetic mechanisms leading to development of insulin resistance and possibly directly contributing to the development of atherosclerosis is disturbed endocrine function of adipose tissue commonly present in patients with obesity and/or type 2 diabetes mellitus (Haluzík et al. 2004, Havel 2002, Housa et al. 2006, Housová et al. 2005).

Cytoplasmic fatty acid binding proteins (FAPBs) are a family of proteins expressed in various tissues including fat, that play an important role not
only in lipid metabolism and other metabolic regulations (Boord et al. 2002). Recent clinical studies have shown that FABP4 produced primarily by adipocytes is released into the circulation suggesting its possible systemic effects (Karpišek et al. 2007, Stejskal and Karpišek 2006, Xu et al. 2006, 2007). It has been demonstrated that FABP concentrations are increased in patients with obesity and/or metabolic syndrome and may represent a novel marker of this clinical entity (Karpišek et al. 2007, Stejskal and Karpišek 2006, Xu et al. 2006). However, there are virtually no studies focused on direct relationship of FABP to insulin sensitivity and diabetes compensation. Here we examined the influence of well-known modulator of lipid metabolism PPAR-α agonist fenofibrate (Guerre-Millo et al. 2000, Haluzík and Haluzík 2006, Haluzík et al. 2006, Staels et al. 1998, Yong et al. 1999) on circulating levels of FABP in patients with obesity and type 2 diabetes mellitus. We hypothesized that some of metabolic effects of fibrates may be mediated by changes of circulating FABP levels. We demonstrate that FABP circulating levels closely correlate with anthropometric measures of obesity, parameters of insulin sensitivity and with measures of diabetes compensation, but they are not affected by fenofibrate treatment.

Methods

Study subjects

Eleven obese females with type 2 diabetes mellitus and serum triglyceride concentrations above 2.0 mmol/l and 10 age-matched healthy normal-weight control women were included into the study. Their body weight remained stable for at least three months before the beginning of the study. The patients were treated with diet, metformin alone or combination of metformin and glimepiride. The diabetic medication remained unchanged from three months before the start throughout entire study. None of the studied subjects suffered from acute infectious disease. Written informed consent was provided by all participants before being enrolled in the study. The study was approved by the Human Ethical Review Committee, First Faculty of Medicine and General University Hospital, Prague, Czech Republic.

Study protocol

Measurements of clinical and hormonal parameters in type 2 diabetes patients were performed at baseline and after 3 months of treatment with PPAR-α agonist – fenofibrate (200 mg, Lipanthyl 267M). Control subjects were examined only once and did not receive any treatment.

Anthropometric examination and blood sampling

All subjects were measured and weighed, body mass index was calculated and blood samples were withdrawn after an overnight fasting. Serum was obtained by centrifugation and stored in aliquots at –70 °C until further analysis.

Hormonal and biochemical assays

Biochemical parameters were measured by standard laboratory methods in the Department of Biochemistry of the General University Hospital. Serum insulin concentrations were measured by commercial RIA kit (Cis Bio International, France). Serum FABP concentrations were measured by commercial ELISA kit (BioVendor, Brno, Czech Republic).

Hyperinsulinemic-isoglycemic clamp

Hyperinsulinemic-isoglycemic clamp is based on the principle established by De Fronzo et al. (1979). Insulin efficiency is evaluated as the amount of glucose necessary to maintain the desired glucose levels under conditions of constant insulin infusion calculated per unit of body weight or body surface. In case of isoglycemic clamp the desired glucose level equals fasting blood glucose level.

At the beginning of the study two cannulas were inserted into forearm veins on both arms. One of the cannulas was used to infuse insulin solution (20 IU HM-R insulin in 20 ml 0.9 % saline solution, infusion rate: 1 mIU/kg/min for patients with BMI <30 kg/m², 40 mIU/m²/min for patients with BMI >30 kg/m²) and glucose solution (20 % glucose solution) + 20 ml 7.5 % KCl in 500 ml 0.9 % sodium saline solution. Glucose infusion rate was modified according to changes of blood glucose concentration). The second cannula in the contralateral forearm was used for blood sampling for blood glucose in 5-min intervals and insulin measurements at baseline and steady-state period. Blood glucose concentration was measured by glucometer (Super Glucocard II, Arkray, Japan). Glucose clamp was finished after 3 h when “steady-state” i.e. period of stable blood glucose concentration close or equal to the desired value was reached for at least 30 min.
The following parameters were calculated based on clamp results: glucose disposal rate (M, mg.kg\(^{-1}\).min\(^{-1}\)) was defined as the amount of glucose supplied by the infusion to maintain the desired blood glucose, glucose disposal rate (M\(_{\text{kerig}}\), mg.kg\(^{-1}\).min\(^{-1}\)) corrected to urine glucose loss, metabolic clearance rate of glucose (MCR\(_{\text{glc}}\), ml.kg\(^{-1}\).min\(^{-1}\)) was expressed as the ratio of glucose disposal rate to blood glucose concentration and the insulin sensitivity indexes (M/I and MCR\(_{\text{glc}}\)/I, mg.kg\(^{-1}\).min\(^{-1}\) per mIU.ml\(^{-1}\), ml.kg\(^{-1}\).min\(^{-1}\) per mIU.ml\(^{-1}\)) were defined as the ratio of M or MCR\(_{\text{glc}}\) and the average insulin concentration during the observed period (steady-state), respectively.

### Results

**The influence of fenofibrate on anthropometric and biochemical parameters**

At baseline, body mass index, serum glucose, triglyceride, insulin, glycated hemoglobin levels and atherogenic index in T2DM group were significantly higher (Table 1), while serum HDL cholesterol concentrations were significantly lower than in control group (Table 1). Three months of treatment with fenofibrate led to a significant decrease of serum triglyceride concentrations (Table 1), while both blood glucose and glycated hemoglobin significantly increased (Table 1). Other parameters including BMI were not affected by fenofibrate treatment (Table 1).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control group</th>
<th>Obese 1</th>
<th>Obese 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m(^2))</td>
<td>23.7±0.8</td>
<td>36.7±2.9*</td>
<td>36.5±2.7*</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td>23.0±2.9</td>
<td>44.2±7.1*</td>
<td>47.5±8.0*</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.39±0.24</td>
<td>5.22±0.32</td>
<td>5.09±0.25</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.55±0.28</td>
<td>1.17±0.11*</td>
<td>1.20±0.11*</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>3.01±0.15</td>
<td>2.74±0.29</td>
<td>2.90±0.19</td>
</tr>
<tr>
<td>Triacylglycerol (mmol/l)</td>
<td>0.98±0.12</td>
<td>2.96±0.39*</td>
<td>2.17±0.24**</td>
</tr>
<tr>
<td>Atherogenic index</td>
<td>1.88±0.09</td>
<td>3.17±0.37*</td>
<td>3.02±0.75*</td>
</tr>
<tr>
<td>Blood glucose (mmol/l)</td>
<td>4.97±0.19</td>
<td>8.48±0.68*</td>
<td>9.43±0.84**</td>
</tr>
<tr>
<td>Glycated hemoglobin (%)</td>
<td>3.81±0.08</td>
<td>5.77±0.56*</td>
<td>6.10±0.58**</td>
</tr>
<tr>
<td>MCR(_{\text{glc}}) (ml.kg(^{-1}).min(^{-1}))</td>
<td>8.41±0.66</td>
<td>2.70±0.44*</td>
<td>2.74±0.61*</td>
</tr>
<tr>
<td>M/I (mg.kg(^{-1}).min(^{-1}) per mIU.ml(^{-1}))</td>
<td>0.062±0.008</td>
<td>0.030±0.005*</td>
<td>0.026±0.0006*</td>
</tr>
<tr>
<td>MCR(_{\text{glc}})/I (ml.kg(^{-1}).min(^{-1}) per mIU.ml(^{-1}))</td>
<td>0.076±0.011</td>
<td>0.021±0.003*</td>
<td>0.017±0.004*</td>
</tr>
</tbody>
</table>

Values are means ± S.E.M. Statistical significance is from one-way ANOVA and Paired t-test respectively. * p<0.05 vs. control group, ° p<0.05 obese group 1 vs. obese group 2. MCR\(_{\text{glc}}\) - metabolic clearance rate of glucose, M/I, MCR\(_{\text{glc}}\)/I - insulin sensitivity indexes

**The influence of fenofibrate on insulin sensitivity**

At baseline, all parameters of insulin sensitivity as measured by hyperinsulinemic-isoglycemic clamp were significantly lower in T2DM relative to control group suggesting blunted rate of glucose disappearance from circulation in response to infused insulin (Table 1). Three months of fenofibrate treatment did not significantly affect any of these parameters (M, M\(_{\text{kerig}}\), MCR\(_{\text{glc}}\), M/I, MCR\(_{\text{glc}}\)/I) (Table 1). All parameters of insulin sensitivity remained significantly lower in T2DM relative to control group after three months of treatment with fenofibrate (Table 1).
The influence of metabolic status, fenofibrate treatment and hyperinsulinemia during clamp on FABP levels

Fasting serum FABP concentrations in T2DM group before treatment with fenofibrate were more than two-fold higher than in control group (p<0.001) and 3 months of fenofibrate treatment did not affect this parameter (Fig. 1).

Ninety minutes of hyperinsulinemia during the clamp tended to decrease FABP levels in control group (non-significant change vs. baseline values) (Fig. 2). 180 min of hyperinsulinemia led to 16 % decrease of FABP levels (p=0.03 vs. baseline levels) (Fig. 2).

In type T2DM patients before fenofibrate treatment, 90 min of hyperinsulinemia during the clamp decreased FABP levels by 20 % (p=0.025) (Fig. 2). 180 min of hyperinsulinemia in T2DM patients before fenofibrate treatment decreased serum FABP levels by 26 % (p=0.017 vs. baseline values) (Fig. 2). The percentage of decrease in FABP levels in T2DM group during the clamp before fenofibrate treatment in both 90th and 180th min was significantly greater than in control group (p=0.03 and 0.009, respectively).

In T2DM patients after 3 months of fenofibrate treatment, 90 min of hyperinsulinemia decreased serum FABP levels by 7 % (non-significant difference vs. baseline values) (Fig. 2). 180 min of hyperinsulinemia in T2DM patients after 3 months of fenofibrate treatment decreased serum FABP levels by 16 % (p=0.036 vs. baseline values). The percentage of decrease in FABP levels during the clamp in T2DM group after 3 months of fenofibrate treatment did not significantly differ from control group any more.

Relationship of serum FABP levels to anthropometric, biochemical and insulin sensitivity parameters

Due to a relatively low number of subjects the relationship of serum FABP levels to anthropometric, biochemical and insulin sensitivity parameters was analyzed in a combined group of healthy controls and T2DM patients before the treatment of fenofibrate. Serum FABP levels positively correlated with BMI (r = 0.80, p<0.001), triglyceride levels (r = 0.74, p<0.001), blood glucose (r = 0.83, p<0.001), glycated hemoglobin (r = 0.70, p<0.001), atherogenic index (r = 0.80, p<0.001) and insulin levels (r = 0.50, p=0.04). An inverse relationship was found between FABP and HDL levels (r = −0.70, p<0.001), FABP and glucose disposal rate (r = −0.67, p=0.002), FABP and glucose disposal rate corrected to urine glucose loss (r = −0.60, p=0.0087), FABP and metabolic clearance rate of glucose (r = −0.77, p<0.001), FABP and M/I insulin sensitivity index (r = −0.73, p<0.001) and FABP and MCRglc/I insulin sensitivity index (r = −0.79, p<0.001), respectively.

Discussion

The most important finding of this study is the fact that circulating levels of FABP are strongly
positively linked to BMI, blood glucose and glycated hemoglobin levels in patients with type 2 diabetes mellitus and have an inverse relationship to the parameters of insulin sensitivity measured by hyperinsulinemic-isoglycemic clamp. FABP thus may represent a novel and a very strong link between disturbed secretory function of adipose tissue and other metabolic abnormalities coupled within insulin resistance syndrome.

It has been previously documented in experimental studies that FABPs have an important role in shuttling of fatty acids to cellular compartments, modulation of intracellular lipid metabolism and regulation of gene expression (Binas et al. 1999, Levy et al. 2001, Wolfrum et al. 2001). For example, intestinal FABP is an important modulator of fatty acid absorption and chylomicron expression (Levy et al. 2001), while heart and liver FABPs are important players in fatty acid oxidation and fatty acid ligand signaling in the liver (Binas et al. 1999, Wolfrum et al. 2001). The fact that liver PPAR receptors bind FABP (Rolf et al. 1995) and that FABP can modulate PPAR function in the nucleus by affecting the transport of PPAR ligands into the nucleus (Wolfrum et al. 2001) led us to test the possibility that PPAR-α activation may in turn affect circulating levels of FABP. Our results show that this is not the case and that 3 months of treatment with PPAR-α agonist fenofibrate had no effect on circulating FABP levels despite its ability to significantly decrease circulating triglycerides and free fatty acids.

However, our study has revealed other interesting relationships between circulating FABP levels and metabolic parameters. First, we have documented a very close positive correlation not only between FABP levels and the degree of obesity as measured by BMI but also even stronger positive correlation between FABP and blood glucose or glycated hemoglobin, respectively. Second, our study is the first one to demonstrate a strong inverse relationship between FABP levels and parameters of insulin sensitivity as measured by hyperinsulinemic-isoglycemic clamp. Our data suggest that circulating FABP levels are directly regulated by insulin as documented by suppression of FABP concentrations during hyperinsulinemic-isoglycemic clamp. Interestingly, the degree of suppression was significantly greater in untreated patients with type 2 diabetes relative to healthy controls suggesting that insulin deficiency and/or insulin resistance may be involved in the increase of FABP levels in type 2 diabetic patients.

Several adipocyte-derived factors have been originally described as important players in the development of insulin resistance and type 2 diabetes mellitus while later studies have shown that they are rather the markers of ongoing metabolic disturbances than its primary cause (Hotamisligil et al. 1993, Steppan et al. 2001). Since there are at present only few studies focused on the significance of circulating FABP levels in the development of insulin resistance in humans and none of them is a prospective one, it is currently unclear whether circulating FABP is only a marker or an active player in this process. Furthermore, it should be noted that not only adipocytes but also immunocompetent cells such as macrophages might be an important source of circulating FABP (Makowski et al. 2005). Nevertheless, it is safe to conclude that FABP is one of the factors most closely related to BMI, diabetes compensation and insulin sensitivity from the wide scale of adipose tissue-derived hormones including the most commonly studied ones such as adiponectin and resistin (Anderlová et al. 2006, McTernan et al. 2002, Weyer et al. 2001).

In summary, our study has documented that circulating FABP levels are strongly related to several features of insulin resistance syndrome. It remains to be determined whether circulating FABP is only the strong marker of ongoing metabolic disturbances or one of its primary causes.

Conflict of Interest
There is no conflict of interest.

Acknowledgements
Supported by Research Project of MHCR MZO VFN 2005 and grant of IGA MHCR No. 8302-5.

References


